The company has an independent magnetic particle chemiluminescence technology platform, independently developed and designed a fully automatic single-part chemiluminescence immunoassay analyzer, and obtained registration certificates for 12 diagnostic reagents in three series, including myocardial markers, inflammatory markers, and gastric function.Projects in the research and registration stages also include more than 30 diagnostic reagents, including thyroid function, hormones, tumor markers, brain injury, acute renal insufficiency, etc.In the future, POCT testing and diagnostic products will be continuously enriched and developed towards intelligent, wearable, and home testing.The company has also established production lines for sprays, powders, gel preparations, and granules to produce various medical device products, erasable products, and daily chemical products for the natural orifices of the human body.Among them, the anti-nasal allergy gel product is an exclusive product with a unique formula and unique dosage form, indicated to use for prevention and treatment of allergic rhinitis and prevention of flu.
Company Profile
Beijing Hongbo Gene Medical Technology Co., Ltd. focuses on the research and development, production and sales of biotechnology and medical devices. The company was listed on the New OTC Market on January 11, 2016, stock number: 835373.The company has established a R&D and production base in Tianjin: Xinlandao (Tianjin) Medical Technology Co., Ltd.The company is also a first-level agent for Roche Diagnostics POC products.